LTR Pharma (ASX:LTP) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma Notes Receivable?

LTR Pharma ASX:LTP -4.27% 15 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

LTR Pharma's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

LTR Pharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Notes Receivable Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
LTR Pharma (ASX:LTP) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Notes Receivable too high?
LTR Pharma's current Notes Receivable is A$0.00 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Notes Receivable compare to VRTX and REGN?
LTR Pharma's Notes Receivable of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on LTR Pharma and its competitors. LTR Pharma's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price